European Commission approves expanded use of Vertex's KAFTRIO for cystic fibrosis patients

From Nasdaq: 2025-04-07 22:32:00

The European Commission has approved an expansion of the label for Vertex Pharmaceuticals’ KAFTRIO for cystic fibrosis patients aged 2 years and older with certain gene mutations. Patients in Austria, Denmark, Ireland, Norway, and Sweden will have access to the therapy soon due to existing reimbursement agreements. Vertex is working with authorities in the EU to ensure access for all eligible patients.



Read more at Nasdaq: Vertex Gains European Approval For Expanded Use Of KAFTRIO In Treating Cystic Fibrosis